SCHEMBL5333026

SCHEMBL5333026

Cn1cc(-c2nccc(Oc3cc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)c(F)cc3F)n2)cn1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 16/20 0.63
BRAF P15056 5/20 0.51
RAF1 P04049 2/20 0.48
MAPK3 P27361 1/20 0.48
RIPK2 O43353 1/20 0.48
ABCB11 O95342 1/20 0.48
ABL1 P00519 1/20 0.48
NR3C1 P04150 1/20 0.48
RET P07949 1/20 0.48
HTR1A P08908 1/20 0.48
PDGFRB P09619 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
KIT P10721 1/20 0.48
CHRM1 P11229 1/20 0.48
BCR P11274 1/20 0.48
FGFR1 P11362 1/20 0.48
RARG P13631 1/20 0.48
PDGFRA P16234 1/20 0.48
FLT1 P17948 1/20 0.48
MAOA P21397 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5335483 0.90 KDR (0.74) KDRBRAFRAF1RIPK2ABCB11
SCHEMBL5451158 0.90 KDR (0.65) KDRBRAFRAF1RIPK2ABCB11
SCHEMBL5425980 0.88 KDR (0.49) KDRRAF1RETPDGFRBPDGFRA
SCHEMBL5429189 0.87 KDR (0.73) KDRBRAFRAF1MAPK3RIPK2
SCHEMBL5444337 0.86 KDR (0.68) KDRBRAFRAF1MAPK3
SCHEMBL5431936 0.85 KDR (0.66) KDRBRAFRET
SCHEMBL5345812 0.79 KDR (0.64) KDRRAF1PDGFRBTEK
SCHEMBL572529 0.78 KDR (0.85) KDRBRAFRAF1RIPK2ABCB11
SCHEMBL17179168 0.78 KDR (1.00) KDRBRAFRAF1RIPK2ABCB11
SCHEMBL5447211 0.76 NTRK1 (0.60) KDRBRAFRIPK2ABL1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
WO-2007076473-A2 SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 WO disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 KDR 555/4885BRAF 1/4885RAF1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.